Catalent, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.catalent.com

Earnings Score

Market Cap $11.43B
PE -46
Debt -
Cash -
EV -
FCF -

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$247.00M
ROE	-5%
Equity	$4.70B
Growth Stability	-412%
PE	-46.26
PEG	-79.03
PB	2.43
Earnings CAGR	3%
Sales CAGR	17%
FCF CAGR	0%
Equity CAGR	31%
Earnings Stability	-0.1
Earnings Growth YoY	-92%

Earnings Growth QoQ	-87%
Earnings CAGR 5Y	1%
Sales CAGR 5Y	8%
Equity CAGR 5Y	9%
Earnings CAGR 3Y	-5%
Sales CAGR 3Y	-5%
Equity CAGR 3Y	-6%
Market Cap	$11.43B
Earnings Score	6%
Shares Growth 3y	1%
Equity Growth QoQ	33%
Equity Growth YoY	0%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.

SEC Filings

Direct access to Catalent, Inc. (CTLT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31
2023
- 10-Q Dec 31
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31
2022
- 10-Q Dec 31
- 10-Q Sep 30
- 10-K Jun 30
- 10-Q Mar 31

Sector Comparison

How does Catalent, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Catalent, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 3%

Stability -10%

loading chart...

Catalent, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Catalent, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	06/2015	06/2016	06/2017	06/2019	06/2020	06/2021	06/2022	06/2023	06/2024	TTM
Net Margins	11%	6%	5%	5%	6%	13%	10%	-6%	-24%	-
ROA	-	7%	7%	-	5%	9%	7%	-2%	-7%	-
ROE	-	17%	15%	-	6%	14%	10%	-5%	-22%	-5%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	06/2015	06/2016	06/2017	06/2019	06/2020	06/2021	06/2022	06/2023	06/2024	TTM
Debt over FCF	-	121.52	13.3	-	-122.65	-13.25	-19.34	-16.84	-84.69	-
Debt over Equity	3.04	3	2.94	1.82	1.08	0.86	0.89	1.14	1.05	-
Growth Stability	-	-	-	92%	100%	100%	100%	-64%	-412%	-412%

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Bad Graham’s Stability (-412%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	06/2015	06/2016	06/2017	06/2019	06/2020	06/2021	06/2022	06/2023	06/2024	CAGR 5Y
Revenue YoY growth	-	1%	12%	21%	23%	29%	21%	-12%	3%	8%
Earnings YoY growth	-	-47%	-1%	20%	31%	206%	-5%	-151%	316%	1%
Equity YoY growth	-	0%	14%	132%	72%	35%	22%	-0%	0%	9%
FCF YoY growth	-	-49%	917%	-81%	-186%	892%	-13%	46%	-82%	-